<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336403">
  <stage>Registered</stage>
  <submitdate>11/01/2011</submitdate>
  <approvaldate>11/01/2011</approvaldate>
  <actrnumber>ACTRN12611000037909</actrnumber>
  <trial_identification>
    <studytitle>Performance of two commonly used supraglottic airway devices in paediatric anaesthesia: laryngeal mask airway vs  i-Gel 
 a randomized controlled trial</studytitle>
    <scientifictitle>Performance of two commonly used supraglottic airway devices in paediatric anaesthesia: laryngeal mask airway vs  i-Gel 
 a randomized controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Supraglottic airway - comparison between Laryngeal Mask Airway and iGel</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients are randomised to receive either an Laryngeal Mask Airway or an igel Airway.
Both devices will be inserted into the mouth using the same technique.
The laryngeal mask airway has an inflatable cuff while the igel has a soft gel cuff.
They will be utilised for the length of the procedure the patient is undergoing (normally 1-4 hours)</interventions>
    <comparator>Laryngeal mask airway: control</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Amount of leakage around the cuff of the supraglottic airway device in ml/kg as defined in the difference between the inspiratory and expiratory tidal volume</outcome>
      <timepoint>prior to surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of sore throat
Outcome will be assessed via a facial pain scale or in older patients a VAS-Scale</outcome>
      <timepoint>3-5 hours post surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of airway trauma (e.g. blood staining)
Assessed via observation of the patient</outcome>
      <timepoint>on removal of the device</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>0-16 years
elective surgery not involveing the airway
weight &gt; 5kg, &lt; 60 kg
No contraindications for use of supraglottic airway device as determined by anaesthetist independent of the study team</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Contraindications for use of supraglottic airway device as determined by anaesthetist independent of the study team, airway malformations, surgery involving the airway
Weight &lt; 5kg or &gt; 60 kg</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All patients will be recruited at the pre-anaesthetic visit. Only patients who meet the inclusion criteria for the study will be enrolled and only after informed consent is given voluntarily by the parent/guardian. The patients will be randomised by computer generated block randomisation. The participant will be assigned the next available Participant Number. The Participant Number will correspond to a numbered randomisation envelope. The randomisation is concealed in the closed envelope and will only be opened by the anaesthetist in charge of the patient at induction of anaesthesia. The participant number will be used to identify the patient for the duration of the study.</concealment>
    <sequence>The patients will be randomised by computer generated block randomisation. Following written informed consent, the participant will be assigned the next available Participant Number. The Participant Number will correspond to a numbered randomisation envelope. The randomisation is concealed in the closed envelope and will only be opened by the anaesthetist in charge of the patient at induction of anaesthesia. The participant number will be used to identify the patient for the duration of the study.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/02/2011</anticipatedstartdate>
    <actualstartdate>15/07/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>18/06/2013</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize>200</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Princess Margaret Hospital for Children</primarysponsorname>
    <primarysponsoraddress>Roberts Road
SUBIACO, WA 6008</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Princess Margaret Hospital for Children</fundingname>
      <fundingaddress>Roberts Road
SUBIACO, WA 6008</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Princess Margaret Hospital Foundation</fundingname>
      <fundingaddress>68 Hay Street
Subiaco
WA 6008</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>School of Medicine and Pharmacolgy</sponsorname>
      <sponsoraddress>University of Western Australia
35 Stirling Highway
Crawley, Perth
Western Australia 6009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To ensure the safe delivery of oxygen and anaesthesia gases to a child, the anaesthetist will insert a tube into the childs mouth. There are two tubes which can be used for this purpose. Both look very similar and do the same thing. One type of tube, the laryngeal mask, has an inflatable soft silicone cuff at the end while the other, called an Igel, has a non-inflatable cuff made of soft gel. Both devices have been independently shown to be safe in childrens anaesthesia. However, a direct comparison between the two devices is lacking in the paediatric population, which we are doing.</summary>
    <trialwebsite />
    <publication>Anaesthesia. 2015 Dec;70(12):1412-7. doi: 10.1111/anae.13206. Epub 2015 Sep 10.
A comparison of the i-gel() and the PRO-Breathe(Â®) laryngeal mask during pressure support ventilation in children.
Drake-Brockman TF1,2, Ledowski T3, Hegarty M1, Gessner M1, von Ungern-Sternberg BS1,3.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Child and Adolescent Health Campus Ethics Committee</ethicname>
      <ethicaddress>Princess Margaret Hospital for Children
Roberts Road, SUBIACO, WA 6008</ethicaddress>
      <ethicapprovaldate>22/03/2011</ethicapprovaldate>
      <hrec>1876 EP</hrec>
      <ethicsubmitdate>17/01/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Britta Regli-von Ungern</name>
      <address>Chair of Paediatric Anaesthesia
Princess Margaret Hospital for Children
Roberts Road
SUBIACO, WA 6008</address>
      <phone>+61893408109</phone>
      <fax />
      <email>britta.regli-vonungern@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Britta Regli-von Ungern</name>
      <address>Chair of Paediatric Anaesthesia
Princess Margaret Hospital for Children
Roberts Road
SUBIACO, WA 6008</address>
      <phone>+61893408109</phone>
      <fax />
      <email>britta.regli-vonungern@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Britta Regli-von Ungern-Sternberg  </name>
      <address>Department of Anaesthesia and Pain management
Princess Margaret Hospital
Roberts Road
Subiaco
WA 6008</address>
      <phone>+61893408109</phone>
      <fax />
      <email>britta.regli-vonungern@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Britta Regli-von Ungern-Sternberg  </name>
      <address>Department of Anaesthesia and Pain management
Princess Margaret Hospital
Roberts Road
Subiaco
WA 6008</address>
      <phone>+61893408109</phone>
      <fax />
      <email>britta.regli-vonungern@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>